# BMPR2

## Overview
BMPR2 is a gene that encodes the bone morphogenetic protein receptor type 2 (BMPR2), a transmembrane serine/threonine kinase receptor. This receptor is integral to the bone morphogenetic protein (BMP) signaling pathway, which is a critical component of the transforming growth factor-beta (TGF-Î²) superfamily. BMPR2 plays a pivotal role in various biological processes including cell growth, differentiation, and apoptosis, primarily through its interaction with type 1 BMP receptors and subsequent activation of SMAD transcription factors. Mutations in the BMPR2 gene are closely associated with pulmonary arterial hypertension (PAH), a severe vascular disease, highlighting its importance in vascular physiology and pathology (Elliott2013Genetics; Machado2015Pulmonary). The receptor's structure, including its kinase domain and unique C-terminal tail, is crucial for its function and interaction with other signaling molecules (Chaikuad2019Structural; Agnew2021Structural).

## Structure
The BMPR2 protein, encoded by the BMPR2 gene, is a type II receptor in the bone morphogenetic protein (BMP) signaling pathway, which is part of the transforming growth factor-beta (TGF-Î²) superfamily. The molecular structure of BMPR2 includes several distinct domains: a short extracellular ligand-binding domain, a single transmembrane domain, a serine/threonine kinase domain, and a unique long C-terminal tail. The extracellular domain is characterized by a disulfide-bonded three-finger toxin fold with one ligand-binding site (Agnew2021Structural). The kinase domain exhibits a bilobal architecture typical of protein kinases, with specific features that characterize the BMP/TGF-Î² receptor family (Chaikuad2019Structural).

BMPR2 is subject to post-translational modifications such as N-linked glycosylation at specific asparagine residues in the extracellular domain, which enhances ligand binding (Lowery2013N-linked). The protein also undergoes phosphorylation, crucial for its signaling function (Kim2017Clinical).

There are two isoforms of BMPR2: a long form that includes the entire C-terminal tail and a short form resulting from a splice variant lacking exon 12, which codes for most of the C-terminal tail. This structural variation affects the receptor's cellular localization and function, particularly in SMAD protein-mediated signaling (Kim2017Clinical).

Overall, the structure of BMPR2 is integral to its role in BMP ligand signaling, influencing various biological processes and linked to diseases such as pulmonary arterial hypertension when mutated (Sanchez-Duffhues2020Bone).

## Function
The BMPR2 gene encodes the type 2 receptor for bone morphogenetic proteins (BMPs), which are part of the transforming growth factor-beta (TGF-Î²) superfamily. This receptor is crucial for various cellular processes including growth, differentiation, and apoptosis across multiple cell types. BMPR2 primarily functions by forming a complex with type 1 BMP receptors. Upon binding with BMP ligands, this complex leads to the phosphorylation and activation of SMAD transcription factors, specifically SMAD1, 5, or 8. These activated SMADs then partner with SMAD4 and move into the nucleus to regulate the transcription of genes that are vital for cellular functions and developmental processes (Kim2017Clinical; Majka2011Physiologic).

In addition to its canonical signaling role, BMPR2 also interacts with other signaling pathways, contributing to its diverse functional roles in the cell. For instance, it is involved in the regulation of endothelial cell behavior, influencing vascular stability and function. The receptor's activity is critical in maintaining the balance between BMP and TGFÎ² signaling, which is essential for tissue homeostasis and preventing diseases such as pulmonary arterial hypertension (Hiepen2019BMPR2).

BMPR2 is expressed in various tissues, including the pulmonary vascular endothelium, cerebellum, and liver, highlighting its importance in both vascular and systemic physiological functions (Kim2017Clinical).

## Clinical Significance
Mutations in the BMPR2 gene are primarily associated with pulmonary arterial hypertension (PAH), a severe condition characterized by high blood pressure in the pulmonary arteries, leading to right heart failure and potentially death if untreated. These mutations are found in both heritable PAH (HPAH) and idiopathic PAH (IPAH), with familial cases showing autosomal dominant inheritance patterns (Elliott2013Genetics; Machado2015Pulmonary). The penetrance of these mutations is notably higher in women (Gamou2018Genetics). 

Clinical outcomes in PAH patients with BMPR2 mutations are generally poorer compared to those without such mutations. These patients often exhibit a more severe disease phenotype, including earlier onset, higher pulmonary vascular resistance, and reduced survival rates (Machado2015Pulmonary). The type and location of BMPR2 mutations can influence the severity of PAH, affecting factors such as age of onset and disease progression (Machado2015Pulmonary).

Beyond PAH, BMPR2 mutations have implications in other health conditions. For instance, they are associated with hereditary hemorrhagic telangiectasia, a disease affecting blood vessel development (Lane2000Heterozygous). These mutations disrupt normal BMPR2 protein function, leading to various cardiovascular defects and impacting pathways crucial for maintaining vascular integrity.

## Interactions
BMPR2 (Bone Morphogenetic Protein Receptor Type 2) engages in several critical interactions with other proteins, which are essential for its function in signal transduction pathways. BMPR2 forms heterodimeric complexes with type I receptors such as ALK2, which are crucial for ligand-induced receptor signaling. This interaction involves the kinase domains of both receptors and is essential for the phosphorylation and activation of downstream signaling molecules like SMADs (Agnew2021Structural). Additionally, BMPR2 interacts with activin A, binding specifically to its extracellular domain with low nanomolar affinity, which is distinct from its interaction with other type II receptors like ACVR2 (Rejon2013Activins).

BMPR2 also interacts with Tctex-1, a dynein light chain. This interaction, which involves the cytoplasmic domain of BMPR2, is crucial for the regulation of dynein's cargo specificity and is influenced by phosphorylation events mediated by BMPR2. Notably, different isoforms of BMPR2 exhibit varying efficiencies in binding and phosphorylating Tctex-1, and mutations in BMPR2 associated with primary pulmonary hypertension do not affect the binding to Tctex-1 but do inhibit its phosphorylation (Machado2003Functional). These interactions underscore the multifaceted role of BMPR2 in cellular signaling and its implications in disease.


## References


[1. (Machado2003Functional) R. D. Machado. Functional interaction between bmpr-ii and tctex-1, a light chain of dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension. Human Molecular Genetics, 12(24):3277â3286, November 2003. URL: http://dx.doi.org/10.1093/hmg/ddg365, doi:10.1093/hmg/ddg365. (157 citations) 10.1093/hmg/ddg365](https://doi.org/10.1093/hmg/ddg365)

[2. (Elliott2013Genetics) C. Gregory Elliott. Genetics of pulmonary arterial hypertension. Clinics in Chest Medicine, 34(4):651â663, December 2013. URL: http://dx.doi.org/10.1016/j.ccm.2013.08.003, doi:10.1016/j.ccm.2013.08.003. (5 citations) 10.1016/j.ccm.2013.08.003](https://doi.org/10.1016/j.ccm.2013.08.003)

[3. (Agnew2021Structural) Christopher Agnew, Pelin Ayaz, Risa Kashima, Hanna S. Loving, Prajakta Ghatpande, Jennifer E. Kung, Eric S. Underbakke, Yibing Shan, David E. Shaw, Akiko Hata, and Natalia Jura. Structural basis for alk2/bmpr2 receptor complex signaling through kinase domain oligomerization. Nature Communications, August 2021. URL: http://dx.doi.org/10.1038/s41467-021-25248-5, doi:10.1038/s41467-021-25248-5. (21 citations) 10.1038/s41467-021-25248-5](https://doi.org/10.1038/s41467-021-25248-5)

[4. (Sanchez-Duffhues2020Bone) Gonzalo Sanchez-Duffhues, Eleanor Williams, Marie-Jose Goumans, Carl-Henrik Heldin, and Peter ten Dijke. Bone morphogenetic protein receptors: structure, function and targeting by selective small molecule kinase inhibitors. Bone, 138:115472, September 2020. URL: http://dx.doi.org/10.1016/j.bone.2020.115472, doi:10.1016/j.bone.2020.115472. (83 citations) 10.1016/j.bone.2020.115472](https://doi.org/10.1016/j.bone.2020.115472)

[5. (Gamou2018Genetics) S. Gamou, M. Kataoka, Y. Aimi, T. Chiba, Y. Momose, S. Isobe, T. Hirayama, H. Yoshino, K. Fukuda, and T. Satoh. Genetics in pulmonary arterial hypertension in a large homogeneous japanese population. Clinical Genetics, 94(1):70â80, January 2018. URL: http://dx.doi.org/10.1111/cge.13154, doi:10.1111/cge.13154. (13 citations) 10.1111/cge.13154](https://doi.org/10.1111/cge.13154)

[6. (Majka2011Physiologic) Susan Majka, Moira Hagen, Thomas Blackwell, Julie Harral, Jennifer A Johnson, Robert Gendron, Helene Paradis, Daniel Crona, James E Loyd, Eva Nozik-Grayck, Kurt R Stenmark, and James West. Physiologic and molecular consequences of endothelial bmpr2 mutation. Respiratory Research, December 2011. URL: http://dx.doi.org/10.1186/1465-9921-12-84, doi:10.1186/1465-9921-12-84. (82 citations) 10.1186/1465-9921-12-84](https://doi.org/10.1186/1465-9921-12-84)

[7. (Rejon2013Activins) Carlis A. Rejon, Mark A. Hancock, Yining N. Li, Thomas B. Thompson, Terence E. HÃ©bert, and Daniel J. Bernard. Activins bind and signal via bone morphogenetic protein receptor type ii (bmpr2) in immortalized gonadotrope-like cells. Cellular Signalling, 25(12):2717â2726, December 2013. URL: http://dx.doi.org/10.1016/j.cellsig.2013.09.002, doi:10.1016/j.cellsig.2013.09.002. (36 citations) 10.1016/j.cellsig.2013.09.002](https://doi.org/10.1016/j.cellsig.2013.09.002)

[8. (Chaikuad2019Structural) Structural consequences of BMPR2 kinase domain mutations causing pulmonary arterial hypertension (15 citations) 10.1101/786756](https://doi.org/10.1101/786756)

[9. (Kim2017Clinical) Myung-Jin Kim, Seon Young Park, Hae Ryung Chang, Eun Young Jung, Anudari Munkhjargal, Jong-Seok Lim, Myeong-Sok Lee, and Yonghwan Kim. Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, bmpr2. BMB Reports, 50(6):308â317, June 2017. URL: http://dx.doi.org/10.5483/bmbrep.2017.50.6.059, doi:10.5483/bmbrep.2017.50.6.059. (28 citations) 10.5483/bmbrep.2017.50.6.059](https://doi.org/10.5483/bmbrep.2017.50.6.059)

[10. (Hiepen2019BMPR2) Christian Hiepen, Jerome Jatzlau, Susanne Hildebrandt, Branka Kampfrath, Melis Goktas, Arunima Murgai, Jose Luis Cuellar Camacho, Rainer Haag, Clemens Ruppert, Gerhard Sengle, Elisabetta Ada Cavalcanti-Adam, Kerstin G. Blank, and Petra Knaus. Bmpr2 acts as a gatekeeper to protect endothelial cells from increased tgfÎ² responses and altered cell mechanics. PLOS Biology, 17(12):e3000557, December 2019. URL: http://dx.doi.org/10.1371/journal.pbio.3000557, doi:10.1371/journal.pbio.3000557. (89 citations) 10.1371/journal.pbio.3000557](https://doi.org/10.1371/journal.pbio.3000557)

[11. (Lane2000Heterozygous) Kirk B. Lane, Rajiv D. Machado, Michael W. Pauciulo, Jennifer R. Thomson, John A. Phillips, James E. Loyd, William C. Nichols, and Richard C. Trembath. Heterozygous germline mutations in bmpr2, encoding a tgf-Î² receptor, cause familial primary pulmonary hypertension. Nature Genetics, 26(1):81â84, September 2000. URL: http://dx.doi.org/10.1038/79226, doi:10.1038/79226. (1641 citations) 10.1038/79226](https://doi.org/10.1038/79226)

[12. (Lowery2013N-linked) Jonathan W. Lowery, Jose M. Amich, Alex Andonian, and Vicki Rosen. N-linked glycosylation of the bone morphogenetic protein receptor type 2 (bmpr2) enhances ligand binding. Cellular and Molecular Life Sciences, 71(16):3165â3172, December 2013. URL: http://dx.doi.org/10.1007/s00018-013-1541-8, doi:10.1007/s00018-013-1541-8. (26 citations) 10.1007/s00018-013-1541-8](https://doi.org/10.1007/s00018-013-1541-8)

[13. (Machado2015Pulmonary) Rajiv D. Machado, Laura Southgate, Christina A. Eichstaedt, Micheala A. Aldred, Eric D. Austin, D. Hunter Best, Wendy K. Chung, Nicola Benjamin, C. Gregory Elliott, MÃ©lanie Eyries, Christine Fischer, Stefan GrÃ¤f, Katrin Hinderhofer, Marc Humbert, Steven B. Keiles, James E. Loyd, Nicholas W. Morrell, John H. Newman, Florent Soubrier, Richard C. Trembath, Rebecca RodrÃ­guez Viales, and Ekkehard GrÃ¼nig. Pulmonary arterial hypertension: a current perspective on established and emerging molecular genetic defects. Human Mutation, 36(12):1113â1127, October 2015. URL: http://dx.doi.org/10.1002/humu.22904, doi:10.1002/humu.22904. (179 citations) 10.1002/humu.22904](https://doi.org/10.1002/humu.22904)